Empagliflozin Gets Priority Review for Heart Failure Independent of LVEF
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
Diagnosis & Disease Information
Empagliflozin Benefits Patients With Heart Failure and Preserved Ejection Fraction
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
Empagliflozin Gets Breakthrough Tx Status for Heart Failure With Preserved Ejection Fraction
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
Empagliflozin Cuts Risk of Hospitalization, Death in HFpEF Patients
The phase 3 EMPEROR-Preserved trial included 5988 adult patients with heart failure with preserved ejection fraction, with and without diabetes.
FDA Panel Votes on Omecamtiv Mecarbil for Heart Failure With Reduced Ejection Fraction
Omecamtiv mecarbil is a selective small molecule cardiac myosin activator.
Resistant Hypertension Effectively Treated With Novel Drug
Blocking the endothelin pathway could represent a new mode of action to lower blood pressure in resistant hypertension, according to investigators.
SGLT-2 Inhibitors Show Benefit in Heart Failure With Preserved Ejection Fraction
Investigators conducted a meta-analysis of randomized controlled trials on the effect of SGLT-2 inhibitors on patients with HFpEF.
Dapagliflozin Beneficial Regardless of Ejection Fraction in Heart Failure
The findings were consistent across key subgroups examined (eg, LVEF<60%, diabetes)
Sotagliflozin Under Review for Heart Failure Treatment
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
Obesity Linked to Heart Failure in Women With Late Menopause
A study was conducted to determine the relationship between obesity, age at menopause, and heart failure incidence.
- Loading...
Loading...
Next post in Cardiology
Loading... 
Loading...